

Ambulatory Pharmacy Education Series - Resistant Hypertension

03/31/2024 to 03/31/2027

Purpose:

Monthly educational sessions on ambulatory care topics that will bring ambulatory care pharmacists together throughout the Avera footprint and work towards increasing pharmacist knowledge on updated guidelines and enhance patient care. This is a recording of the live sessions that was designed to educate and discuss management options for resistant hypertension.

Objectives:

- 1 Describe basic information about resistant hypertension
- 2 Evaluate therapeutic options for the treatment of resistant hypertension
- 3 Discuss appropriate drug therapy for the treatment of resistant hypertension

Target Audience:

Pharmacist

For successful completion:

- Watch video
- Complete post-test
- Complete evaluation

Accreditation & Credit Designation:

Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Avera is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Education Credit Designation(s)

Pharmacy CE: Avera designates this activity for 0.50 ACPE contact hour(s). ACPE Universal Activity Number (UAN): JA0008079-0000-24-031-H01-P. Pharmacists and pharmacy technicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be uploaded to the NABP CPE Monitor® within 30 days after the activity completion. Per ACPE rules, Avera does not have access nor the ability to upload credits requested after the evaluation closes. It is the responsibility of the pharmacist or pharmacy technician to provide the correct information (NABP ID and DOB (MMDD)) to receive credit.

Additional Information:

Feedback person for this educational activity is: annette.johnson2@avera.org

Enduring Material available from 03/31/2024 to 03/31/2027

- This course content was reviewed on 03/15/2024

Disclosure Policy:

Due to the regulations required for CE credits, all conflicts of interest that persons in a position to control or influence the education must be fully disclosed to participants. In observance of this requirement, we are providing the following disclosure information: all relevant financial relationships disclosed below have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Annette 5123 Johnson, PharmD	Content Expert - Committee Member, Faculty, Lead Planner	Nothing to disclose
Rachelle Davis, PharmD, BCACP	Committee Planning Member	Nothing to disclose

